Raymond James Maintains Strong Buy on Apellis Pharmaceuticals, Lowers Price Target to $89
Portfolio Pulse from richadhand@benzinga.com
Raymond James analyst Steven Seedhouse has maintained a 'Strong Buy' rating on Apellis Pharmaceuticals (NASDAQ:APLS) but lowered the price target from $156 to $89.
August 01, 2023 | 8:24 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Despite a lowered price target, Apellis Pharmaceuticals retains a 'Strong Buy' rating from Raymond James, indicating continued confidence in the company's prospects.
The lowered price target may initially cause some investor concern, potentially leading to short-term price volatility. However, the maintained 'Strong Buy' rating indicates that the analyst still sees significant potential in the company, which could stabilize the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100